| Drug General Information |
| Drug ID |
D0E2OK
|
| Former ID |
DIB016921
|
| Drug Name |
MAL formulation
|
| Synonyms |
MAL formulation (oral, opiate dependence)
|
| Indication |
Opiate dependence [ICD9: 304; ICD10:F11]
|
Phase 2 |
[1]
|
|---|
| Company |
D&A Pharma
|
| Target and Pathway |
| Target(s) |
Mu-type opioid receptor |
Target Info |
Agonist |
[2]
|
|---|
| Kappa-type opioid receptor |
Target Info |
Agonist |
[2]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addictionhsa04080:Neuroactive ligand-receptor interaction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Enkephalin releaseP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Opioid prodynorphin pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
TCR Signaling Pathway
|
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
Opioid Signalling
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of D&A Pharma. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of D&A Pharma. |
|---|
